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 15 
Abstract 16 
The vital roles of microtubule in mitosis and cell division make it an attractive 17 
target for antitumor therapy. Colchicine binding site of tubulin is one of the most 18 
important pockets that have been focused on to design tubulin-destabilizing agents. 19 
Over the past few years, a large number of colchicine binding site inhibitors (CBSIs) 20 
have been developed inspired by natural products (NPs) or synthetic origins, and 21 
many moieties frequently used in these CBSIs are structurally in common. In this 22 
review, we will classify the CBSIs into classical CBSIs and non-classical CBSIs 23 
according to their spatial conformations and binding modes with tubulin, and 24 
highlight the privileged structures from these CBSIs in the development of tubulin 25 
inhibitors targeting the colchicine binding site.  26 
Keywords: microtubule • privileged structures • tubulin inhibitors • colchicine 27 
binding site inhibitors • colchicine domain • prodrug. 28 
 29 
Microtubules are formed by the association of α- and β-tubulin heterodimers, and 30 
serve as important components of the cytoskeleton in eukaryotic cells. They are 31 
extremely important in the process of mitosis and cell division, which make them an 32 
important target for anti-cancer drugs [1]. Microtubules are not simple equilibrium 33 
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polymers, instead they show complex polymerization dynamics which are crucial to 1 
their cellular functions. Microtubule targeting agents (MTAs) that stabilize or 2 
destabilize microtubule can interfere with these microtubule dynamics, which lead to 3 
mitotic block and cell apoptosis [2].  4 
Microtubule targeting agents 5 
Unlike the targets involved in signal transduction and transcriptional regulation, 6 
MTAs have not been shown to have a cancer-specific function without affecting 7 
normal cells [3]. Even though microtubule is not a disease-causing target, this 8 
intervention is promising in cancer therapy because microtubule is essential for tumor 9 
cell proliferation regardless the expected adverse effects on normal cells. However, 10 
due to the highly rapid proliferation of tumor cells, their dynamic microtubule system 11 
is more vulnerable than normal cells, which makes tumor cells more sensitive to 12 
MTAs. 13 
MTAs can potently alter microtubule dynamics at low concentrations, and at 14 
relatively higher concentrations (10-100 times higher), they can block mitosis and 15 
induce cell apoptosis by destabilizing or stabilizing microtubules, based on which 16 
they can be divided into two classes including microtubule destabilizing agents and 17 
microtubule stabilizing agents [2]. At least three binding sites in tubulin have been 18 
identified which can be interfered by MTAs including taxane, vinca alkaloid, and 19 
colchicine binding sites. Inhibitors targeting taxane binding sites can stabilize 20 
microtubule while those targeting the vinca alkaloid and colchicine binding sites can 21 
destabilize microtubule [4]. All these microtubule-binding agents can alter 22 
microtubule dynamics, thus their main potential mechanism of action seems to be the 23 
specific inhibition of the dynamics of mitotic spindle microtubules. However, the 24 
colchicine site binders that destabilize microtubule can also exhibit anti-angiogenesis 25 
and vascular disruption activities which are not found in other site binders [5]. 26 
These three binding sites in tubulin all have natural ligands with high affinity to 27 
the respective binding pocket, which provides many opportunities for the 28 
development of anti-cancer agents with potential activities or druggability. However, 29 
most of the NPs targeting taxane and vinca alkaloid binding sites, such as paclitaxel 30 
and vinblastine, have extremely complex structures. Although total synthesis or 31 
semi-synthesis methods have been developed, the structural complexity and low 32 
aqueous solubility as well as limited availability of source materials hampered their 33 
clinical applications. Besides, multidrug resistance (MDR) and dose-limiting toxicity 34 
caused by the established taxane and vinca alkaloid binding sites inhibitors in cancer 35 
therapy have also limited their applications. As for the colchicine binding site, natural 36 
CBSIs, such as colchicine, combretastatin A-4 and podophyllotoxin, have relatively 37 
simpler structures which can be easily modified. Thus, the emerging CBSIs that have 38 
the potential to overcome these limitations represent a promising type of anti-tubulin 39 
agents, especially those accessible synthetic CBSIs by high throughput screening or 40 
rational drug design. 41 
Over the past two decades, many research efforts have been concentrated on 42 
developing CBSIs inspired by natural sources or synthetic origins. Drug design 43 
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methods including scaffold hopping, bioisosterism, conformation restricting, prodrug 1 
strategy or computer-aided drug design have been utilized to overcome the drawbacks 2 
encountered during the development of CBSIs. To better understand the common 3 
structures of these CBSIs and provide insights into the development of CBSIs in 4 
future, herein we review the development of CBSIs from the perspective of privileged 5 
structures shared by the CBSIs. The frequently used prodrug strategies to improve the 6 
aqueous solubility and bioavailability of CBSIs will be uncovered in this review. 7 
Colchicine domain 8 
Colchicine domain is the generalized naming of colchicine binding site, which 9 
comprises a main site (colchicine binding site) and additional neighboring pockets. 10 
Massaroti et al. [4] have divided the colchicine domain into three zones including 11 
zones 1, 2, and 3. The zone 1 is located at the α subunit interface and surrounded by 12 
residues Valα181, Serα178, Metβ259, and Asnβ258. The zone 2 is an accessory 13 
hydrophobic pocket located in the β subunit and formed by residues Lysβ352, 14 
Asnβ350, Ileβ378, Valβ318, Alaβ317, Alaβ316, Leuβ255, Lysβ254, Leuβ252, 15 
Alaβ250, Leuβ248, Leuβ242, and Cysβ241. And the zone 3, which is buried deeper in 16 
the β subunit, is formed by residues Thrβ239, Valβ238, Tyrβ202, Gluβ200, Pheβ169, 17 
Asnβ167, Glnβ136, and Ileβ4 (Figure 1A).  18 
Owing to the chemical instability of tubulin, the structural information of ligands 19 
binding to the colchicine-binding site was not clear until Ravelli et al. first reported 20 
the structure of α,β-tubulin complexed with N-deacetyl-N-(2-mercaptoacetyl) 21 
colchicine (DAMA−colchicine, PDB code 1SA0) [4]. This pioneering work 22 
illuminated the location of colchicine in the pocket where it prevents curved tubulin 23 
from adopting a straight conformation, which inhibits assembly. As shown in Figure 2, 24 
the methoxy group in ring A of colchicine forms a hydrogen-bond interaction with 25 
Cysβ241 while ring C interacts with the α subunit by a hydrogen bond formed 26 
between the carbonyl group of ring C and the backbone of Valα181. 27 
To date, several compounds with diverse structures have been crystallized in the 28 
colchicine binding site of tubulin [4, 6, 7], which showed many new and interesting 29 
binding modes and provided rationales for the design or discovery of new ligands 30 
targeting this domain. Based on the analysis of María-Jesús Pérez-Pérez et al. [8], 31 
colchicine domain ligands were classified into classical and non-classical CBSIs 32 
according to their spatial orientations. The superposition of these ligands with X-ray 33 
crystal structures indicated that classical CBSIs with more globular or butterfly like 34 
shape occupy zones 1 and 2, mimicking the colchicine-binding mode. However, 35 
non-classical CBSIs with more planar structures tend to locate deeper into the 36 
β-subunit making use of zones 2 and 3 (Figure 1B, 1C). 37 
Privileged structures of CBSIs 38 
A vast number of CBSIs with diverse structures have been developed inspired by 39 
natural sources and synthetic origins in the past two decades. Many fragments namely 40 
privileged structures shared by these CBSIs are frequently found in the construction 41 
of molecules with potent tubulin polymerization inhibition and anti-proliferative 42 
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activities. Many of these privileged structures could be interchanged with retained or 1 
better biological activities, thus some experiential rules may be applied to develop 2 
novel CBSIs. To better understand the tremendous research results achieved in last 3 
two decades and provide rationales for the development of novel CBSIs in the future, 4 
herein we summarize these privileged structures of both classical CBSIs and 5 
non-classical CBSIs, and the privileged prodrug forms are also highlighted. 6 
Classical CBSIs 7 
Typically, this class of CBSIs characterized with a “ aromatic 8 
ring–bridge–aromatic ring” scaffold mostly has globular or butterfly like shape 9 
forming a specific spatial conformation so that they can be accommodated into the 10 
binding pocket. As depicted in Figure 1B, these ligands locate ring A in zone 2, ring B 11 
in zone 1 and the bridge in the space between α and β tubulins. In this section, 12 
privileged structures of ring A, ring B and bridge will be discussed, respectively. 13 
Ring A of classical CBSIs 14 
The trimethoxyphenyl moiety that derived from natural occurring CBSIs such as 15 
colchicine, combretastatins, podophyllotoxin is one of the most important fragments 16 
regarded as ring A of classical CBSIs. It plays a crucial role in interacting with tubulin, 17 
nevertheless, many other structures have also been discovered to replace the 18 
trimethoxyphenyl with retained or better biological activities. Due to the relatively 19 
ample space of zone 2, ring A of classical CBSIs can tolerate variations. However, the 20 
hydrophobic character of this cavity and a critical Cysβ241 residue determine whether 21 
these units are suitable. Thus, these moieties are generally hydrophobic or can form 22 
specific interactions such as hydrogen bond or covalent bond with residues in zone 2.  23 
(1) Trimethoxyphenyl   24 
  The most remarkable privileged structures as ring A is trimethoxyphenyl. 25 
Luduena and Roach evaluated the binding affinities of several compounds bearing 26 
3,4,5-trimethoxyphenyl fragment (trimethoxy benzaldehyde, trimethoxybenzylalcohol) 27 
with tubulin and found that these fragments can inhibit the binding of colchicine to 28 
tubulin at micromole concentrations, suggesting that this moiety can solely act as 29 
weak CBSI occupying zone 2 without ring B and bridge [9]. To date, hundreds of 30 
CBSIs comprising the trimethoxyphenyl moiety have been developed and some of 31 
them are investigated in clinical trials (Figure 3A). 32 
Colchicine (1), the first discovered tubulin destabilizing agent extracted from the 33 
poisonous meadow saffron Colchicum autumnale L, has been the powerful antimitotic 34 
agent to study the tubulin target. Even though the dose-limiting toxicity of colchicine 35 
restrains its application as an anti-cancer agent, it exerts critical roles in this field 36 
since it innovated the subsequent CBSIs developments. The trimethoxyphenyl moiety 37 
of ring A of colchicine plays a crucial role in tubulin binding, it binds to the 38 
hydrophobic pocket by a hydrogen bond with Cysβ241 residue (Figure 2). Insertion of 39 
a bulky group in ring A or replacement of trimethoxyphenyl caused loss of activity 40 
[10]. The tropolone ring of ring C in colchicine skeleton is also a key structural 41 
moiety for its binding to tubulin, which can also be substituted by other similar 42 
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structures. ZD6126 (2) with hexatomic ring replacing tropolone of colchicine was 1 
developed by AstraZeneca, it exhibits potential anti-angiogenesis and antineoplastic 2 
activities, however, the clinical study in phase II was terminated due to the apparent 3 
cardiotoxicity at pharmacological doses [11, 12].  4 
Despite the remarkable biological activity of colchicine in microtubule 5 
depolymerization, its undesirable action such as toxicity, multidrug resistance (MDR) 6 
has stimulated the exploration of new CBSIs with improved anti-cancer activity and 7 
low systemic toxicity. However, the development of CBSIs has been standstill until 8 
another impressive natural CBSI bearing trimethoxyphenyl moiety was discovered. 9 
Combretastatin A-4 (3, CA-4), a natural cis-stilbene derivative isolated from the bark 10 
of the African willow tree Combretum caffrum, is a typical tubulin inhibitor binding to 11 
the colchicine binding site and possesses a simpler and easier synthesized structure 12 
compared to colchicine [13]. Combretastatin A-4 has strong cytotoxicity against a 13 
variety of tumor cells with a broader therapeutic window, thus it has initiated the 14 
discoveries of a large number of combretastatin analogues for overcoming its 15 
isomerization to the less active trans-form. Some prodrug forms or analogues of CA-4 16 
have already been evaluated in clinical trials, such as CA-4P (4), Oxi4503 (5), 17 
AVE8062 (6), Phenstatin (7), CC-5079 (8), BCN-105P (9), CDK-516 (12) (Figure 18 
3A). 19 
The trimethoxyphenyl, cis-olefin and para-methoxyphenyl moieties on the ring 20 
B are the key components of combretastatin structure, and trimethoxyphenyl group 21 
exerts the most dominant effects on modulating the pharmacological properties [14]. 22 
Molecular modelling methods showed that this motif in CA-4 resembles the binding 23 
mode of colchicine though tubulin–CA-4 complex has not been reported so far [15]. 24 
The modifications of CA-4 analogues have been focused on the ring B and the bridge 25 
while the trimethoxyphenyl moiety is generally fixed, these contents will be detailed 26 
in the corresponding sections.  27 
Podophyllotoxin (10), extracted from dried roots of Podophyllum peltatum, was 28 
also found to inhibit microtubule assembly, it competitively inhibits the binding of 29 
colchicine to the colchicine binding site [16]. The antimitotic properties of 30 
podophyllotoxin are similar to those of colchicine possibly because of the overlap of 31 
their binding sites. However, these molecules do not show complete overlap in the 32 
binding site. The trimethoxyphenyl moiety of colchicine and podophyllotoxin have 33 
different binding modes in the pocket of tubulin
 
[17]. The trimethoxyphenyl of 34 
podophyllotoxin is critical to the microtubule depolymerization activity while the 35 
4’-demethylation of trimethoxyphenyl leads to the loss of anti-tubulin activity, which 36 
can be exemplified by etoposide (13) and teniposide (14). Both have a different 37 
mechanism of interfering with topoisomerase II and causing DNA damage [18], 38 
because the oxidative metabolism of 4’-phenol gives 3’, 4’-catechol derivatives which 39 
can be further oxidized to 3’, 4’-ortho-quinone. These two structures cause DNA 40 
damage through forming free radicals or covalent bonds between the quinone and the 41 
DNA [19] (Figure 3B). This case also strengthens the significance role of 42 
trimethoxyphenyl moiety as a privileged structure in maintaining tubulin binding 43 
ability.  44 
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(2) Nitrogenous heterocycles 1 
Nitrogen heterocyclic moieties are often present in privileged structures that are 2 
mostly found in drugs. Replacing methine (CH) of benzene by nitrogen atom 3 
generates nitrogen containing heterocycles, such as pyridine or pyrimidine which are 4 
important structures in medicinal chemistry. The introduction of nitrogen atom greatly 5 
improves the basicity of the system due to its basic character, furthermore, the 6 
protonation of nitrogen turns it into a strong hydrogen bond thus it provides additional 7 
hydrogen bonding interaction. Another important property of nitrogen-containing 8 
heterocycles is polarity which can be used as a mean of reducing the lipophilic 9 
character and improving water solubility and oral absorption. These heterocycles have 10 
been applied in the construction of CBSIs [20]. Herein, we mainly focus on the 11 
substitution of trimethoxyphenyl with these heterocyclic structures which can interact 12 
to the zone 2 of colchicine binding pocket. 13 
In 2008, Nilantha Sirisoma firstly reported some aminoquinazolines endowed 14 
with potent cytotoxic effects, compounds 15 and MPC-6827 (16) showed the most 15 
potent cytotoxicity against multiple tumor cell lines with IC50 values of 2-10 nM [21]. 16 
Afterwards, they proposed and validated tubulin as the main target of these 17 
compounds [22]. Early clinical trials of MPC-6827 was carried out for patients with 18 
advanced cancer [23], however, this promising candidate has been discontinued by 19 
Myrexis Corporation in order to reallocate resources towards advancing lead 20 
candidates from earlier stage programs.  21 
Aleem Gangjee et al. also discovered some similar structures, compound 17 22 
exhibited excellent anti-proliferative activity in searching for receptor tyrosine kinase 23 
(RTK) inhibitors [24]. However, mechanism studies validated that 17 was not a RTK 24 
inhibitor but tubulin binding agent. Studies of the structure-activity relationships 25 
(SARs) suggested that N-methyl and 4-methoxy groups appear important for the 26 
potent activity [25]. Recently, compound 18 with a furo[2,3-d]pyrimidines structure 27 
exhibited potent activity with GI50 values less than 10 nM in a panel of cancer cell 28 
lines, the biological effects of 18 was identified as a novel, potent microtubule 29 
depolymerizing agent [26]. 30 
 Studies independently researched by Xiao-Feng Wang et al.[27]
 
afforded a similar 31 
compound 19 [28, 29], it showed extremely high cytotoxicity against a panel of 32 
human tumor cell lines with GI50 values ranging from 1.5 to 1.7 nM. Extensive SARs 33 
studies on the tetrahydroquinoline moiety have found that six or seven membered ring 34 
was desirable for activity. Compound 20 showed a comparable activity to 19, both of 35 
them strongly inhibited colchicine binding to tubulin indicating that they can interact 36 
with the colchicine binding pocket of tubulin as CBSIs [30]. 37 
All these cases show that aminoquinazoline fragment is a privileged structure 38 
utilized in the design of CBSIs, and N-methyl, 4-methoxy groups are essential for 39 
potent activity. However, recent work carried out by Mouad Alami et al. affording 21 40 
and 22 showed that N-methyl and aminoquinazoline could be respectively replaced by 41 
olefin and 2-methyl quinoline with more potent activity [31, 32]. Molecular modelling 42 
experiments illustrated that 2-methyl quinoline interacts with zone 2 of colchicine 43 
domain by a hydrogen bond between N-1 and Cysβ241 residue, resembling a similar 44 
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positioning with trimethoxyphenyl of IsoCA-4 [32]. These interesting results testify 1 
this new 2-methyl quinoline privileged structure could replace the traditional 2 
trimethoxyphenyl group, which may provide a new direction for discovering 3 
structurally novel CBSIs with potent activities. 4 
(3) Dimethylbenzopyran  5 
Dimethylbenzopyran motif is frequently found in secondary metabolites isolated 6 
from natural sources, many NPs containing this fragment exhibit a wide range of 7 
promising biological activities [33]. Millepachine (23) (Figure 5), first isolated from 8 
the Millettia pachycarpa by Lijuan Chen’s group [34], was found to have potent 9 
cytotoxicity against a variety of human cancer cells. Modifications of millepachine 10 
have led to the discovery of many derivatives with more potent activity, such as 24 11 
[35], 25 [36], 26 [37], 27 [38]. These structures were found to be tubulin 12 
polymerization inhibitors by binding at the colchicine site. Among these compounds, 13 
27 showed higher anti-tubulin polymerization activity than colchicine, the 14 
bioavailability of the hydrochloride salt of 27 was up to 47%, and it significantly 15 
inhibited tumor growths in four xenograft models including resistance-tumor bearing 16 
mice models without causing significant loss of body weight [38]. All these results 17 
indicate that 27 can be developed as a promising new orally active anti-cancer agent, 18 
and it is worth mentioning that 26 and 27 possess a structural similarity with the 19 
chalcones type compound 85 . 20 
(4) Covalent privileged structures.  21 
Irreversible inhibitors also represent an important class of CBSIs, they 22 
irreversibly bind into the colchicine binding pocket by covalent bonds formed with 23 
some specific residues. These binding modes may circumvent drug resistance caused 24 
by mutations of tubulin residues and trigger microtubule disruption. 25 
Urea moiety is one of the most common structures of covalent CBSIs, and it can 26 
be found in the structures of N-Phenyl-N’-(2-chloroethyl)urea (CEU) (28) and its 27 
analogues (29-31) (Figure 6). These anti-tubulin agents can acylate Gluβ198 that is a 28 
residue located in a pocket adjacent to the colchicine binding site [39, 40]. Urea 29 
moiety of CEU could be a bioisostere of the trimethoxyphenyl, which has been 30 
validated by the hybrid compound 32 with potent anti-proliferative activity at 31 
micromolar level [41]. Gaudreault’s group reported the cyclisation of the CEU moiety 32 
into the corresponding phenylimidazolidin-2-ones (IMZs) 33 [42], leading to a new 33 
class of anti-tubulin agents. Cis-olefin moiety can also be replaced with sulfonate or 34 
sulfamide groups as the bridge, thus the obtained compounds 34 [43] and 35 [44] 35 
exhibited potent biological activities. However, these IMZs with steric hindrance can 36 
prevent the IMZ moiety from binding to the adjacent pocket behind colchicine 37 
binding site, thus they may take a different positioning from that of 32. Molecular 38 
modeling experiments showed that the IMZ moiety might mimic the tropolone or the 39 
vanillin moieties of colchicine and CA-4, respectively to stretch into zone 1 of the 40 
pocket[45], which is validated by the most active compound 33 that bears a 41 
trimethoxyphenyl moiety. 42 
Another important structure used as covalent CBSIs is pentafluorphenyl, a 43 
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clinical evaluated compound T138067 (36) and its analogue T113242 (37) can 1 
covalently alkylate tubulin Cysβ241 residue and induce microtubule depolymerization 2 
[46]. Other new anti-tubulin agent PRR 112378 (38) with a novel structure has been 3 
isolated by Combeau et al.[47]
 
from the fresh water plant Ottelia alismoides. This 4 
highly cytotoxic compound with an IC50 of 0.02 nM against KB cell is an efficient 5 
inhibitor of tubulin polymerization (IC50 1.2 μM), it may covalently bond with the 6 
thiol of Cys241 residue by a 1,6-michal addition reaction. A simplified analogue 39 7 
with potent anti-proliferative activity has also been reported by Tsai-Yuan Chang et 8 
al.[48]. 9 
Ring B of classical CBSIs. 10 
Generally, ring B of typical CBSIs can accommodate into zone 1 of colchicine 11 
domain and usually forms a hydrogen bond with the residues around. This moiety of 12 
classical CBSIs lacks variation due to the relatively narrow hydrophobic cavity of 13 
zone 1. Two proper groups that can exactly accommodate into zone 1 are 14 
4-methoylphenyl and indoles, which will be briefly discussed in this section. 15 
(1)  4-methoylphenyl 16 
This motif derived from natural CBSIs such as CA-4, colchicine (a similar 17 
tropolone motif) was often templated in the development of CBSIs. Structurally, the 18 
presence of a para-methoxy group is required for the biological activity; steric effect 19 
in ring B plays a determinative effect on activity; substitutions with an ethoxy or 20 
propoxy group or methylthio group cause a loss in activity [49]. The meta position 21 
tolerates variations which could be electron-donating (e.g., amino, 40) (Figure 7A) or 22 
electron-withdrawing groups (e.g., fluorine, 41). Hydroxyl and amino groups are most 23 
used substitutions introduced at this position, such as CA-4 (3) and AC7700 (40). 24 
Other variations including boronic acid (42) and azide group (43) have been reported 25 
with maintained activities [50, 51].  26 
2-Methoxyestradiol (2-ME, 44) (Figure 7B) is an endogenous estrogen 27 
metabolite with potent inhibition on tumor vasculature and tumor cell growth by 28 
binding to the colchicine binding site of tubulin [52]. The 4-methoylphenyl motif of 29 
2-ME exerts a crucial role in its activity. Due to the formation of sulfate conjugates of 30 
3- and 17-hydroxyl groups, its rapid metabolization and poor pharmacokinetic (PK) 31 
profiles have launched the synthesis and biological evaluation of novel 2-ME 32 
analogues. Potter’s group has been engaged in developing novel 2-ME analogues with 33 
metabolically stable and improved anti-tubulin properties, the modifications were 34 
mainly made on the sheltering of two hydroxyl of 2-ME. The introduction of 35 
sulfamate into 3-hydroxyl resulted compounds 45 and 46 with 15-33 folds of 36 
improvement in anti-proliferative activities against MCF-7 cell lines compared with 37 
2-ME [53]. The 18-OH position of 2-ME tolerates modifications, compounds 47, 48, 38 
49, 50, and 51 all exhibited potent cytotoxicities in nanomolar ranges [54-57]. 39 
Replacing the 3-hydroxyl with amide group is another approach to improve the 40 
metabolic stability, resulting the discovery of ENMD-1198 (52) [58], which is found 41 
to be a new CBSI and is being evaluated in ongoing clinical trials. A simplified 42 
structure mimicking the spatial conformation of 2-ME has been reported, 43 
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tetrahydroisoquinoline derivative 53 [59] exhibited potent cytotoxicity with improved 1 
physicochemical properties. 2 
(2) Indoles 3 
Indole, an important nucleus of many biologically active natural and synthetic 4 
products, represents one of the most important privileged structures in drug discovery. 5 
It occurs in a wide range of therapeutically important drugs with various biological 6 
activities. Indole is one of the most successfully studied heterocyclic rings that can 7 
replace the 4-methoylphenyl motif in CA-4 or colchicine, most of these CBSIs 8 
incorporating indole moiety are derived from synthetic sources. Indole molecules as 9 
inhibitors of tubulin polymerization are continuing to attract the interest of chemists 10 
and biologists [60, 61], herein we will focus on the indole privileged structures as the 11 
ring B of CBSIs.  12 
Indole as ring B of CBSIs was initiated by Liou et al. [62] with the discovery of 13 
compound 54 and 55 (Figure 8). SARs studies revealed that a methoxy group located 14 
at the C-6 position of 3-aroylindole (54) or C-5 position of 1-aroylindole (55) resulted 15 
in the best activity. In continuation of their works on 1-aroylindoles, Liou et al. 16 
developed 4-hydroxy (56a) and 4-amino-1-aroylindoles (56b) as potent tubulin 17 
polymerization inhibitors [63], suggesting that the introduction of hydroxyl or amino 18 
group at C-4 position of 1-aroylindoles was an effective way to increase the 19 
cytotoxicity. The effectiveness of this strategy was also proven by Ty et al. taken in 20 
3-aroylindole resulting in the discovery of 57a and 57b [64]. It is evident that the 21 
indole moieties in these compounds all shared similar structures to 4-methoylphenyl. 22 
2-aroylindoles were also identified by Mahboobi et al.
 
as antimitotic agents, 23 
compound 58 exhibited the most potent activity with IC50 value of 0.06 μM against 24 
HeLa cells [65]. A series of 2-, 3-, 4-, 5- and 6-aroylsindoles were prepared by Liou et 25 
al., compound 59 was the most active with IC50 values ranging from 10 to 15 nM in 26 
six different cancer cell lines, suggesting that substitution on C-5 position of indole 27 
ring may be the best option for this class of CBSIs [66]. Interestingly, when 28 
allocolchicinoids analogue 60 was incorporated with indole moiety based on 29 
colchicine skeleton, it showed higher anti-proliferative activity with IC50 value of 30 
1nM against BJAB cell line [67]. All these cases indicate that indole moiety could be 31 
an alternative of 4-methoylphenyl as the ring B of CBSIs. 32 
 33 
The Bridge of classical CBSIs 34 
The potent antiangiogenic and antitumor profiles of CA-4 open up a new era of 35 
CBSIs since its discovery. However, isomerization of the active cis-olefinic 36 
conformation into the corresponding inactive trans-analogs impedes its clinical 37 
development, thus hundreds of CA-4 analogues have been developed by modification 38 
on cis-double bond. This linkage between two aromatic rings tolerates modifications 39 
due to the ample space where olefin structure is located in the pocket. These moieties 40 
all share a common character that the unique spatial conformation can orient ring A 41 
and ring B into the cavities of zone 2 and zone 1, respectively. Such moieties 42 
including cis-olefin, one atom bridge, chalcones, heterocycles and sulfonamides are 43 
discussed in this section. 44 
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(1) Cis-olefin 1 
Cis-olefin occurred in CA-4 remains the most classical and original bridge, it 2 
initiates the modifications on this cis-double bond to avoid the isomerization of 3 
cis-olefin to trans-olefin. Hydrogenation of the double bond leads to erianin (61) 4 
(Figure 9) that retains activity but with less potent. Studies extending the bridge via 5 
methylene, ethylene, propylene, and butylene revealed that two carbon linkers were 6 
the most active and other linkers were less active both in cytotoxicity and tubulin 7 
assays [68].  8 
(2) One atom bridge 9 
IsoCA-4 (62) with two aromatic rings on one alkenyl carbon represents another 10 
class of CBSIs resembling the structure of CA-4, which showed comparable activity 11 
with that of CA-4 [69]. Another compound comprising indole nucleus in this class is 12 
63 [70], which has
 
tubulin polymerization inhibition value in the submicromolar range 13 
and cytotoxicity in the subnanomolar range. Isoerianin (64), the hydrogenation form 14 
of isoCA-4, exhibited excellent anti-proliferative activity against HCT-116 cells with 15 
IC50 value of 28 nM [71]. Substitution of the double bond with carbonyl leads to 16 
phenstatin (65) with comparable activity of CA-4 [72]. Replacing the isovanillic ring 17 
with an indole (54) [62]
 
or an aniline derivative (66) [73] also led to new compounds 18 
with potent activities. 19 
Amino group is an important privileged linkage, the amino is often substituted 20 
with a methyl and this N-methyl group plays a vital role in maintaining activity 21 
probably because the introduction of methyl leads to a triangle pyramidal shape which 22 
could orient ring A and ring B into the pocket of zone 2 and zone 1, respectively. As 23 
Soussi et al. described [74], compound 67 exhibited potent activity with IC50 value of 24 
7 nM against HCT 116 cells. N-methyl in other aforementioned structures (15-18) 25 
also validated this unit as a privileged structure in the construction of CBSIs. 26 
(3) Chalcones 27 
The length of the bridge can be extended with maintained biological properties, 28 
which is exemplified by two series of compounds including vinylogous analogues of 29 
CA-4 and chalcones. Vinylogous analogues bearing two olefinic bonds have four 30 
geometric isomers while only one of which is active (68) [75]
 
(Figure 10). The 31 
development of 68 as a tubulin inhibitor was hampered due to its synthetic 32 
inaccessibility, while chalcones that can be prepared by the simple procedure are 33 
adaptable for further exploitation.  34 
Chalcone with a α,β-unsaturated ketone structure represents a key structural 35 
motif in biologically active molecules both from synthetic and natural sources. 36 
Research regarding the anti-tubulin activity of chalcones was initiated by Ducki et al., 37 
69 and 70 showed remarkable anti-proliferative activities with respective IC50 values 38 
of 4.3 nM and 0.21 nM against K562 cell lines [76]. The introduction of methyl on α 39 
position of carbonyl led to a dramatically improved cytotoxicity due to the more 40 
preferential s-trans conformation adopted by 70, while s-cis conformation by 69. 41 
Other substitutions on α position of carbonyl have been reported by Lawrence et al. 42 
[77] and Ducki et al. [78] with a conclusion that methyl introduced on α position of 43 
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carbonyl remains the best substitution for activity improvement. The vital effect of 1 
methyl on activity was confirmed by the work of Jun Yan et al. , compound 72 was 70 2 
folds more potent than 71 with IC50 value of 3 nM against A549 cell lines [79]. Since 3 
tubulin was identified as the potential target for chalcone-type compounds, extensive 4 
researches have been carried out to design and synthesize new anti-tubulin cytotoxic 5 
chalconoids, which have been reviewed by Mirzaei et al. [80] recently. Thus, 6 
α,β-unsaturated ketone especially a methyl substituted moiety is a privileged structure 7 
to replace cis-olefin as the bridge of CBSIs.  8 
The spatial relationship between the two aromatic rings of CA-4 and colchicine 9 
is an important structural feature that determines its ability to bind to tubulin. The 10 
enone structure of chalcones is a semi-rigid backbone with three rotatable bonds. As 11 
mentioned above, substitution on α position can act as a conformational locker forcing 12 
the enone to adopt an s-trans conformation, which presumably increases the affinity 13 
of chalcone to tubulin. Thus, enone rigidification may be an approach for activity 14 
improvement. The first attempt by Lawrence et al. promoted the synthesis of 73 and 15 
74, both showed potent cytotoxicity against K562 cell lines with IC50 values ranging 16 
from 40 to 50 nM [81]. In 2015, Xingshu Li’s group systematically studied these 17 
rigidified chalcones with the finding that five-membered ring fused into ring A may 18 
be the best option, compound 75 showed potent activities with IC50 values ranging 19 
from 172 to 570 nM against several cancer cell lines [82]. In their efforts to continue 20 
the research of rigidified chalcones as anti-tubulin agents, compound 76 with an 21 
indole nucleus was found to possess potent cytotoxicity against several cancer cell 22 
lines and exhibited greater than 217-fold selectivity over human normal cells [83]. 23 
Other conformation locking strategy of fusing enone structure into ring B was 24 
reported by Romagnoli’s group, compounds 78 [84] and 79 [85] templated from 77 25 
[86]
 
were all endowed with promising activities. 26 
(4) Heterocycles 27 
Heterocycles as one of the most studied privileged bridges are effective 28 
cis-locked structures to fix the cis double bond in CA-4. The ample space where 29 
olefin structure located in the pocket allows expansion of double bond to a larger 30 
fragment, such as heterocycles. This heterocycle bridged strategy has enriched the 31 
library of CA-4 analogues since the first attempt was made by Shirai et al. through 32 
replacing the olefinic moiety with dioxolane scaffolds (80), however, it was devoid of 33 
anti-tubulin activities [87]. To date, a large number of this class of analogues with 34 
retained anti-tubulin activities have been reported and detailed reviews can be found 35 
in the summaries of Yan Lu et al. [88]
 
and Pérez-Pérez et al. [8]. The privileged 36 
heterocyclic rings include heteroaromatic rings such as pyrazole (81), imidazole (82), 37 
1,3-oxazole (83), [89] triazols (84) [90], tetrazoles (85) [91], furazan (86) [92], 38 
2-aminothiazoles (87)
 
[93], N-methyl imidazole (88) [94] and other nonaromatic 39 
heterocycles such as β-lactams (89 [95], 90 [96] and 91 [97] ) (Figure 11). All these 40 
hetero-aromatic compounds share five-membered heterocycle rings as the bridge, 41 
suggesting that five-membered rings seem to be the best option for this class CBSIs. 42 
The exceptions of four-membered rings are β-lactams, compounds 89-91 with 43 
β-lactams as the bridge showed impressive cytotoxicity, C-3 aryl substituted 90 and 44 
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91 with better activities indicate that this position tolerates modifications probably 1 
because another ample space exists in the corresponding zone of colchicine binding 2 
site. 3 
(5) Rings fused into ring B 4 
Fusing cis-olefin into ring B represents another tactic to lock the cis double bond. 5 
The works of fusing carbocyclic rings into ring B were mainly described by Pinney’s 6 
and Alami’s groups. Pinney’s group was the first to attempt this modification leading 7 
to the discovery of 92 (Figure 12) with seven membered carbocyclic ring fused into 8 
vanillin ring. Compound 92 exhibited highly potent cytotoxicity against several 9 
human cancer cell lines with IC50 values ranging from 3.2 to 28 pM [98]. Templated 10 
with the structure of 92, other molecules were successively reported by both groups. 11 
For examples, 93 [99],
 
94 [100], 95 [101], 96
 
[102] all exhibited potent activities. 12 
Recently, Xingshu Li’s group described the fusing of carbocyclic rings into indole 13 
nucleus, compound 97 with seven membered ring was the most active with IC50 14 
values ranging from 22 to 56 nM [103]. Heterocycles fused into ring B have also been 15 
achieved by Galli et al. [104], compound 98 showed similar cytotoxic and 16 
anti-tubulin activities compared with CA-4 in neuroblastoma cells but a better PK 17 
profile. All these cases suggest that rings especially seven membered rings fused into 18 
ring B are privileged motifs mimicking the structure of colchicine.  19 
(6) Sulfonamides 20 
Sulfonamides have long been privileged structures in drug discovery. Drugs with 21 
sulfonamide motif have many biological activities, such as antibacterial, diuretic, 22 
antidiabetic, antithyroid, antihypertensive and antiviral activities. Sulfonamide 23 
structures can be alternative of cis-olefin to act as the bridge as exemplified by 24 
clinically investigated compounds 36, 37, 99 [105], and 100
 
[106] (Figure 13). 25 
Another important application of sulfonamide in CBSIs is ABT-751 and its analogues, 26 
these compounds bearing planar or rigid structures tend to be located deeper into the 27 
β-subunit. Therefore, they are grouped into the non-classical class and will be 28 
discussed in the relevant section. Other bridges comprising sulfonamide were 29 
described by Reddy’s group, the discoveries of 101 [107] and 102 [108] with 30 
remarkable antitumor activity led to the most potent compound 103 [109], which was 31 
proved to be an anti-tubulin agent with highest anti-proliferative activity having IC50 32 
value of 3 nM against K562 cell lines. 33 
 34 
Non-classical CBSIs 35 
Unlike the classical CBSIs that share a common structure (ring A, ring B and a 36 
bridge), these non-classical CBSIs are characterized with diverse structures. Their 37 
space conformations are generally planar or rigid skeletons that is capable to stretch 38 
into the deeper zone 2 of the β-subunit (Figure 1C). Naturally derived CBSIs 39 
including plinabulin and nocodazole or synthetic origins, such as ABT-751 and its 40 
analogues, anthracenones, will be reviewed in this section.  41 
Diketopiperazine 42 
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Diketopiperazines are cyclodipeptides obtained by the condensation of two 1 
α-amino acids, and they are often found alone or embedded in larger, more complex 2 
architectures in a variety of NPs. These privileged structures have several 3 
characteristics that make them attractive scaffolds for drug discovery. The 4 
conformational constrained heterocyclic scaffolds with stability to proteolysis mimics 5 
a preferential peptide conformation that has the ability to bind to a wide range of 6 
targets [110].
 
 7 
Phenylahistin (104) (Figure 14) with a 2,5-diketopiperazine skeleton was firstly 8 
isolated by Kanoh et al. from Aspergillus ustus as a racemic mixture, the enantiomer 9 
(−)-104 exhibited potent cytotoxicity with inhibition of tubulin polymerization [111]. 10 
Compound 105, the dehydrogenation form of 104, was reported as an antimitotic 11 
agent being 1,000 times more active than (−)-104. The tert-butyl derivative 106 was 12 
developed by Hayashi’s group with 2.8 folds increase in cytotoxic potency compared 13 
with 105 [112]. SARs studies on the tert-butyl and the phenyl groups of 106 afforded 14 
compounds 107 with a 2,5-difluorophenyl and 108 with a benzophenone, both were 15 
found to have more potent activities with 5.7 and 10 folds increase in cytotoxicity 16 
against HT-29 cell lines, respectively
 
[113]. Modifications of benzophenone and 17 
tert-butyl of 108 led to the discovery of 109
 
[114]
 
and 110 [115], 109 exhibited 18 
increase in potency of 2.8 folds, however, 110 with pyridine replaced of tert-butyl 19 
imidazole slightly decreased in potency of 5 folds, as compared with 108. 20 
Due to the intermolecular hydrogen bonds and π-π stacking interactions from 21 
lines or networks of 2,5-diketopiperazine, this class of CBSIs shares a limitation of 22 
poor solubility. Aiming at solving this drawback, Yonghong Liu’s group introduced 23 
protective groups to replace one or two of the amide hydrogen atoms, thus the 24 
formation of hydrogen bonds and π-π stacking interactions were interrupted. 25 
Compounds 111
 
[116]
 
and 112
 
[117]
 
were endowed with improved solubility, however,  26 
their activities were decreased with IC50 values ranging from 0.36 to 4.5 µM against 27 
several cell lines. 28 
Benzimidazoles 29 
Benzimidazoles derivatives (BZs) characterized by carbamate substituted at the 30 
position 2, such as albendazole (ABZ), fenbendazole (FBZ), mebendazole (MBZ),  31 
oxibendazole (OBZ), parbendazole (PBZ), and luxabendazole (LBZ) (Figure 15) are 32 
commonly used for antinematodal treatment. They are also very effective anti-tumor 33 
agents, it was believed that BZs can exert their cytotoxic effects by disrupting the 34 
functions of the microtubule system [118]. Thus, BZs may represent a new class of 35 
structurally novel antimitotic agents as tubulin inhibitors. Some of them are currently 36 
being investigated in clinical trials, for example, nocodazole (114) is a 37 
rapidly-reversible inhibitor of microtubule polymerization with potential antitumor 38 
activity, and is often used as a lead compound for the discovery of novel CBSIs. 39 
Another compound in clinical study is MN-029 (115), this L-alanine prodrug of 40 
MN-022 (116) is rapidly metabolized to its active form 116 in vivo. Other than 41 
carbamate substitution on the benzimidazole ring, benzimidazole-2-urea derivatives 42 
were reported by Wenna Wang et al., compound 117 showed promising cytotoxic 43 
activity with IC50 values ranging from 6 nM to 1.77 µM [119]. 44 
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Unlike CA-4 or colchicine, these BZs do not interact with the α-subunit but are 1 
located into the deeper site of β-tubulin, this site overlaps very little with that of 2 
colchicine.
 
Meanwhile, the benzimidazole-carbamate structure can accommodate into 3 
zone 3 of colchicine domain to form hydrogen bonds with residues Asnβ165 and 4 
Gluβ198 [6]. This unique binding mode of BZs with tubulin provides new insights 5 
into the discovery of CBSIs with benzimidazole-2-carbamate moiety.      6 
ABT-751 and its analogues 7 
ABT-751 (118) and its analogues sharing a characteristic structure of 8 
benzsulfamide have long been studied as structurally unique CBSIs since ABT-751 9 
was identified as a potent anti-proliferative agent [120], and was subsequently found 10 
to be an anti-tubulin agent by targeting the colchicine binding site [121]. ABT-751 11 
interacts with all three zones in its X-ray structure reported by Audrey Dorle a´ns et 12 
al.[122], which is distinct from all reported binding modes with tubulin. The 13 
4-methoylphenyl is accommodated into zone 1 with pyridine ring in zone 2, and the 14 
phenol extends into the deeper site of β-tubulin, namely zone 3 with phenolic 15 
hydroxyl formed hydrogen bonds with Tyrβ202 residue. ABT-751 was the only 16 
known ligand occupying all the three zones in colchicine domain until Yan-Na Liu et 17 
al. [123] reported that the m-ethoxyaniline group of 119 with a novel rigid skeleton 18 
extends into zone 3 of colchicine binding pocket with hydrogen bonded with Tyrβ202, 19 
while ethyoxyl substituent at the 6-position occupied only partial hydrophobic cavity 20 
in zone 1 with the adjacent acetamide group formed a hydrogen bond with Serα178 at 21 
the interface (Figure 16A). 22 
Due to the conjugation effect of pyridine nitrogen, the structure of 23 
diphenylamine moiety is almost planar, thus it can be accommodated into the 24 
colchicine binding site. Numerous ABT-751 analogues with the similar spatial 25 
conformation have been acquired since the discovery of ABT-751. Takashi Owa et al. 26 
[124] first identified E7070 (120) (Figure 16B) as a potent anti-cancer agent with a 27 
conformation-locking strategy, this strategy of fusing the secondary amine into ring B 28 
was testified as an effective tactic to maintain the planar conformation. Subsequently, 29 
Jing-Ping Liou’s group [125, 126] synthesized the compound 121, 122, 123 by a 30 
similar way to prove that fusing the secondary amine into ring B with the opposite 31 
orientation was more effective. The IC50 values of 121-123 ranged from 8 to 40 nM 32 
against a panel of cancer cell lines. The secondary amine fused into ring A has also 33 
been reported by Nicolas Lebegue’s group, while sulfamide was replaced with ethyl, 34 
the resulting compound 124
 
[127] exhibited potent cytotoxicity against L1210 cells 35 
with IC50 value of 110 nM. However, lack of chemical and metabolic stability of 124 36 
led to relatively lower in vivo antitumor activity, which provoked their continuing 37 
work to overcome these drawbacks. A more stable quinazolinone motif was 38 
introduced to replace the previous three membered ring, the afforded compound 125 39 
showed more potent activities both in vitro and in vivo [128]. Another analogue 40 
HMN-214 (126) (prodrug of 127) with trans-olefin replaced with sulfamide was 41 
originally discovered and developed by Nippon Shinyaku, it showed strong antitumor 42 
activity by causing M-phase arrest of tumor cells and inducing apoptosis, and is 43 
currently undergoing clinical trials against various tumor types. However, this 44 
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compound showed no interaction with tubulin [129]. 1 
Anthracenone   2 
Molecules comprising anthracenone skeleton are another representative 3 
structurally planar CBSIs. This class of CBSIs was started from Helge Prinz’s group, 4 
compound 128  (Figure 17) showed remarkable cytotoxicity with IC50 of 20 nM 5 
against K562 cell lines by targeting colchicine binding site of tubulin [130]. This 6 
unique anthracenone motif in 128 motivated their efforts to continue the research on 7 
this class of CBSIs, compounds 129
 
[131], 130
 
[132], 131 [133], 132 [134], and 133 8 
[135] were discovered to exhibit potent anti-proliferative and anti-tubulin activities. 9 
The binding mode had not been elucidated until 134 was suitably docked into 10 
colchicine domain with a hydrogen bond formed between methanone group and 11 
Valα181 as well as two cation-π interactions formed between the phenyl rings and 12 
Lysβ352 and Lysβ254 [136]. All these cases showed that anthracenone is a privileged 13 
structure in the skeletons of non-classical CBSIs. 14 
Prodrugs of CBSIs 15 
CBSIs either from natural sources or synthetic origins usually suffer from poor 16 
aqueous solubility and PK profiles that hinder the progression of these CBSIs in 17 
preclinical studies or clinical evaluations. Many strategies to improve aqueous 18 
solubility of CBSIs have been centered on making use of prodrug strategy or 19 
searching for new structures with improved solubility. Herein, the frequently used 20 
prodrug forms will be discussed including phosphate, amino acid introduced at 21 
hydroxyl or amino groups and other forms. Other delivery systems such as polymeric 22 
micelles, liposomes, dendrimers to improve the poor aqueous solubility and PK 23 
properties will not be covered here. 24 
Phosphate  25 
The most classical strategy is the derivatization as the phosphate prodrugs which 26 
have good chemical stability and also are rapidly converted to the active drugs in vivo 27 
by phosphatases. This approach is often applied to the prodrugs bearing a phenolic 28 
hydroxyl group as exemplified by CA-4P (4) (Figure 18). CA-4P has excellent water 29 
solubility, good stability and potent cytotoxicity, which is rapidly dephosphorylated to 30 
CA-4 in vivo within a few minutes. CA-4P is currently being investigated in phase 3 31 
clinical trials for the treatment of anaplastic thyroid cancer and in phase 2 clinical 32 
trials for non-small cell lung cancer and platinum-resistant ovarian cancer [137]. 33 
Other than phenolic hydroxyl group, the NH in indole ring of CBSIs is also a good 34 
modifiable position to produce phosphate prodrug. For example, water solubility of 35 
compound 72-P was increased to 125 mg/mL in sodium phosphate buffer, and the t1/2 36 
of 72-P (157.5 min) was greatly improved in comparison with CA-4 (t1/2 < 60 min ), 37 
which may lead to a higher bioavailability in vivo [79].  38 
Amino acid  39 
Like phosphate prodrugs, amino acid prodrugs can also increase aqueous 40 
solubility. This modification strategy is usually applied in prodrugs with an amino 41 
group. As the aqueous solubility improvement is expected, amino acid conjugation 42 
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strategy may also increase the cell uptake of prodrugs in aid of peptide transporters. 1 
An example of this approach is 135, the amino acid prodrug of CA-4, which is being 2 
investigated in clinical trials for advanced-stage soft tissue sarcoma, solid tumors and 3 
advanced solid tumors [138].  4 
Others  5 
Other approaches to improve aqueous solubility include hydrochloride (6, 136) 6 
[139]
 
and carboxylate (137). Compound 137 is the prodrug of plinabulin, and it was 7 
developed by Hayashi’s group [140] via a synthetic methodology [141]. This novel 8 
modification method to improve the aqueous solubility of plinabulin provides a new 9 
modification site for this class of CBSIs. 10 
Conclusion & future perspective  11 
NPs with structurally diverse frameworks have always been the inspiration for the 12 
development of small druggable molecules [142]. NPs inspired CBSIs discovery is a 13 
powerful and economical strategy to develop the novel CBSIs, which avoids the 14 
time-consuming de novo design for scaffold production. To overcome the limitations 15 
encountered in the development process of these natural CBSIs, such as colchicine, 16 
CA-4 and phenylahistin, synthetic alternatives that possess better cytotoxic and PK 17 
profiles have been discovered using these NPs as the templates.  18 
In addition, structural biology has greatly accelerated the development of CBSIs 19 
since the identification of complexes of α,β-tubulin with a wide range of structurally 20 
diverse ligands. Knowing their binding modes with tubulin, those established CBSIs 21 
can be modularly analyzed and their pharmacophore models may be constructed, which 22 
facilitates medicinal chemists to discover more structurally novel CBSIs.  23 
As mentioned throughout this perspective, privileged structures are often 24 
overlapped within different classes. These privileged structures that share common 25 
characters possess similar interactions with tubulin within the colchicine binding 26 
pocket. With these common characters available, more alternatives resembling the 27 
established privileged structures can be discovered and further validated. Thus, 28 
off-targets or failing works could be avoided with this privileged structure based 29 
strategy taken into account. We anticipate this review will provide such insights into 30 
the development of novel CBSIs in the future. 31 
 32 
 33 
 34 
 35 
 36 
 37 
 38 
 39 
 40 
 41 
 42 
 43 
JU
ST
 A
CC
EP
TE
D
 1 
Financial & competing interests disclosure 2 
The authors acknowledge the National Natural Science Foundation of China (No. 3 
81373280; 81673306), The Open Project of State Key Laboratory of Natural 4 
Medicines, China Pharmaceutical University (No. SKLNMKF 201710), and China 5 
Postdoctoral Science Foundation (No. 2015M581903) for financial support. 6 
No writing assistance was utilized in the production of this manuscript. 7 
 8 
 9 
 10 
Executive summary 
Background 
 Microtubules are formed by the association of α- and β-tubulin heterodimers and serve as 
important components of the cytoskeleton in eukaryotic cells. 
 The vital roles of microtubule in mitosis and cell division make it an attractive target for 
antitumor therapy. 
Microtubule targeting agents 
 Tubulin inhibitors can be divided into three classes according to their binding sites in 
microtubule, including taxane, vinca alkaloid, and colchicine binding sites. 
 Colchicine binding site inhibitors have been attractive over the past two decades, hundreds of 
structurally diverse CBSIs have been developed.  
Colchicine domain 
 Colchicine domain is the generalized naming of colchicine binding site, it comprises a main 
site (colchicine binding site) and additional neighboring pockets. 
 Inhibitors targeting colchicine domain are classified into two classes including classical 
CBSIs and non-classical CBSIs based on their spatial structures. 
Privileged structures in CBSIs 
 Privileged structures in CBSIs are discussed based on classical CBSIs and non-classical 
CBSIs, respectively. 
 Classical CBSIs are typically characterized with an “aromatic ring – bridge – aromatic ring” 
which have a globular or butterfly like shape, and privileged structures of these three 
fragments are highlighted. 
 Non-classical CBSIs are usually characterized with more planar or rigid skeletons, and they 
are structurally different from the common structures of colchicine and CA-4 analogues. 
Prodrugs of CBSIs 
 Some prodrug forms frequently used to improve aqueous solubility and PK profiles are 
highlighted.  
 The most classical form is the phosphate prodrug due to its good chemical stability and 
metabolic profiles. 
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Figure 1．Three zones in the colchicine binding site (A), and classical (B) and non-classical (C) CBSIs 4 
binding modes with tubulin in colchicine binding site. 5 
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Figure 2. The structure of colchicine and its binding mode with tubulin (PDB code: 1sa0). 2 
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Figure 3. A) Structures bearing trimethoxyphenyl moiety in clinical trials. B) Demethylation of 2 
podophyllotoxin leads to loss of tubulin depolymerization activity but DNA topo II activity obtained.  3 
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Figure 4. Nitrogenous heterocyclic compounds. 6 
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Figure 5.  Modifications of millepachine bearing dimethylbenzopyran moiety. 2 
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Figure 6. Structures bearing covalent privileged moieties. 6 
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Figure 7.  A) Structures bearing 4-methoylphenyl moiety. B) Structures derived from 2 
2-Methoxyestradiol. 3 
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Figure 8. Structures bearing indole moiety. 7 
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Figure 9. Cis-olefin and one atom as the bridge of classical CBSIs. 2 
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  4 
Figure 10. Chalcone structures as the bridge of classical CBSIs. 5 
 6 
 7 
Figure 11. Heterocycles as the bridge of classical CBSIs. 8 
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Figure 12. Structures with rings fused into ring B. 2 
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Figure 13. Sulfonamide moiety as the bridge of classical CBSIs. 5 
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 7 
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Figure 14. Non-classical CBSIs bearing the diketopiperazine moiety. 9 
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Figure 15. Non-classical CBSIs bearing the benzimidazole moiety 12 
 13 
JU
ST
 A
CC
EP
TE
D
 1 
Figure 16.  A) Binding modes of ABT-751 and 119 with tubulin. B) The modifications of ABT-751 as 2 
the non-classical CBSIs. 3 
 4 
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Figure 17. Structures bearing anthracenone moiety. 6 
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Figure 18. Privileged prodrug forms of CBSIs. 2 
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